Swapnil Bhargava is the Senior Vice President of CMC Development and GMP Manufacturing at AbCellera. He is responsible for building process development, MSAT, manufacturing, and supporting CMC capabilities to deliver optimal therapeutic antibodies from discovery to the clinic. Before joining AbCellera, Swapnil worked at Seagen as VP for drug substance process development, where he was responsible for leading cell line development, upstream and downstream, conjugation and analytical sciences departments. Prior to Seagen, Swapnil worked at Amgen leading process development efforts for different modalities, including biosimilars. Swapnil has supported multiple INDs and BLAs and has contributed to bringing multiple modalities to clinic and market. Swapnil has a doctorate in Chemical Engineering from University of Maryland and a BS and MS from the Indian Institute of Technology (IIT) Delhi.